Navigation Links
Xlumena Closes Series C Financing; Focuses on Expanding Global Commercial Presence and Obtaining FDA Clearance
Date:12/3/2013

MOUNTAIN VIEW, Calif., Dec. 3, 2013 /PRNewswire/ -- Xlumena, Inc., a leader in the development of advanced endoscopic devices, today announced the close of a $25 million Series C financing.  Led by Third Point LLC, the round of funding includes existing investors Prism VentureWorks, Charter Life Sciences, Ascent Biomedical Ventures and Aperture Venture Partners.  Xlumena will use the Series C proceeds to expand global commercialization efforts for its AXIOS family of devices and continue the process of bringing this innovative platform to the US interventional endoscopy community. 

Xlumena's principal product, the AXIOS Stent and Delivery System, obtained a CE mark designation in Europe in 2012 and is available in a select number of centers.  The AXIOS Stent, a fully-covered, dual-flanged stent, is delivered under endoscopic ultrasound guidance and designed to create a secure drainage pathway between the gastrointestinal tract and the common bile duct, gallbladder or pseudocyst.  The HOT AXIOS, also available in Europe, incorporates cautery into the delivery system, enabling access and stent delivery in a single device.  The AXIOS devices have been used in the treatment of acute cholecystitis, biliary inflammation associated with strictures or stones in the bile duct, and pancreatic pseudocysts.

Greg Patterson, President and CEO of Xlumena, commented: "As a company, we have always focused on the needs of interventional endoscopists. This financing will allow us to better meet the global commercial demand and provide a springboard for an initial launch of the AXIOS in the United States once FDA clearance is granted. We look forward to this new collaboration with Third Point and a continued partnership with our existing investors."  Jason Hong Ph.D. will represent Third Point LLC on the Xlumena Board of Directors. 

For more information about the AXIOS Stent and Delivery System, please visit www.xlumena.com.

About Xlumena, Inc.: Xlumena is the leader in developing products that enable advanced image-guided endoscopy procedures. These innovations will allow endoscopists to offer minimally invasive alternatives to patients suffering from common gastrointestinal and biliary conditions. Pioneering interventional endoscopists around the world are using Xlumena's products to extend their therapeutic reach. 

About Third Point: Third Point LLC is an SEC-registered investment adviser headquartered in New York. Founded in 1995, Third Point follows an event-driven approach to global investing.

CAUTION: The AXIOS and HOT AXIOS devices have CE mark designation in Europe. They are not available for sale in the United States. 


'/>"/>
SOURCE Xlumena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Tyber Medical Closes Private Placement Funding Round
2. Catabasis Closes $32.4 Million Series B Financing
3. CorMedix Inc. Closes $3,000,000 Preferred Stock Offerings
4. TREVENTIS Corporation Closes $4.4 Million Financing with Wellcome Trust
5. Apama Medical, A Shifamed Portfolio Company, Closes $3.2M Series A-1 Financing Round
6. MEDTEC China 2013: Conference Program Closes in on Finalization
7. Drip Drop Inc. closes $3.0M Series A-1 round with investments from John Elway, Ronnie Lott, and Sam Nazarian.
8. Acutus Medical Closes Series B Funding at $28 Million
9. Organovo Holdings, Inc. Closes $46.6 Million Public Offering of Common Stock and Exercise of Over-Allotment Option
10. Endexx closes Acquisition of Dispense Labs LLC.
11. AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
(Date:3/29/2017)... 2017 NetworkNewsWire Editorial Coverage  ... There are a ... regulating marijuana, but economic arguments also favor its legalization. The ... enforcement costs. However, to legalize and regulate marijuana requires an ... (OTC: SING) ( SING Profile ), American Cannabis Company (OTC: ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 ... ... cannabis market. According to a new report published by New Frontier ... by 2020. The accelerating pace of cannabis legalization in ... of legalizing cannabis, are considered to be a major factor that ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
(Date:3/29/2017)... , ... March 29, 2017 ... ... and South Hills of Pittsburgh now have easier access to the robotic-assisted ... by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the ... American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd ... Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
Breaking Medicine News(10 mins):